Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
acquired by a larger company in 2021
|
| gptkbp:collaborations |
academic institutions
|
| gptkbp:focus |
genomic profiling
|
| gptkbp:founded |
2012
|
| gptkbp:founder |
gptkb:Michael_A._Dyer
|
| gptkbp:goal |
personalized medicine
|
| gptkbp:headquarters |
gptkb:Buffalo,_New_York
|
| https://www.w3.org/2000/01/rdf-schema#label |
OmniSeq
|
| gptkbp:market |
gptkb:United_States
international |
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:products |
gptkb:OmniSeq_Comprehensive
OmniSeq Immune |
| gptkbp:regulatoryCompliance |
FDA_clearance
CLIA_certification |
| gptkbp:research_focus |
cancer diagnostics
|
| gptkbp:services |
gptkb:OmniSeq_Target
gptkb:OmniSeq_Insights |
| gptkbp:technology |
bioinformatics
next-generation sequencing |
| gptkbp:website |
www.omniseq.com
|